
Hims & Hers (HIMS) stock has crash more than 25% in recent sessions after Novo Nordisk (NVO) filed a sweeping patent-infringement lawsuit targeting the company’s semaglutide offerings.
This legal punch follows a U.S. Food and Drug Administration (FDA) crackdown on unapproved GLP-1 compounding, forcing HIMS to abruptly abandon its new $49 oral Wegovy alternative.